AccurKardia is an ECG-led diagnostics software company. We are unlocking the value of the ECG signal towards broad diagnostics coverage and disease management in cardiology and beyond. This holds the key to improving clinical outcomes and saving lives at a planetary scale. AccurKardia's first product, AccurECG is an FDA cleared (Class II SaMD), cloud-based, and device agnostic software for fully automated ECG interpretation and detection for up to 13 arrhythmias. It is intended to assist cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate in July 2023.
